Physician profile
Muhammad Babar
NPI 1891749305
$2,128.79
in general payments reported to CMS, 2019-2025
14 companies · $60.54 in 2025
The $60.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $253 · 2021: $455 · 2022: $258 · 2023: $206 · 2024: $188 · 2025: $60.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $680.55 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $469.90 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $298.73 | 2019-2022 | |
| Ucb, INC. | $176.41 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $101.39 | 2019 | |
| Acadia Pharmaceuticals INC | $78.00 | 2019 | |
| Pfizer INC. | $77.98 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.08 | 2023-2024 | Xifaxan |
| Pharmacosmos Therapeutics INC. | $59.08 | 2024 | Monoferric |
| Melinta Therapeutics, LLC | $38.16 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.32 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $20.90 | 2025 | Zerbaxa |
| Advanced Respiratory, INC | $15.81 | 2019 | |
| Boston Scientific Corporation | $13.48 | 2024 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.